Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic BackgroundBarry R. Davies, Martin Pass|Molecular Cancer Therapeutics|2012Cited by 460
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Rachel Schiff, Martin J. Shea et al.|Breast Cancer Research|2014Cited by 70